# Stefan S. Bielack

Source: https://onco.cc/people/stefan-bielack/  
OnCo record `stefan-bielack` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leads the COSS group and co-led EURAMOS-1, the largest osteosarcoma trial ever run.

## Summary

Stefan Bielack (Stuttgart) chairs the Cooperative Osteosarcoma Study Group and was a lead investigator of EURAMOS-1, the 2,260-patient international trial showing that neither adding ifosfamide-etoposide for poor responders nor interferon for good responders improves outcomes over MAP chemotherapy, fixing MAP as the global standard. His COSS registry analyses define prognostic factors in osteosarcoma.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: paediatric; osteosarcoma; cooperative-group
- Role: Head of Paediatric Oncology, Klinikum Stuttgart Olgahospital; Chair, Cooperative Osteosarcoma Study Group
- Specialisms: Osteosarcoma; Paediatric oncology; Bone tumours; International trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Bielack%20SS%5BAuthor%5D%20osteosarcoma

## Connected records

- cancers: [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- institutions: [Klinikum Stuttgart / Olgahospital](https://onco.cc/institutions/klinikum-stuttgart-olgahospital/)

---
JSON: https://onco.cc/api/v1/entities/stefan-bielack.json